FEELM
FEELM launched its new innovative disposable vape solution FEELM Max, at the Vaper Expo UK 2023 in Birmingham on May 13.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230514005039/en/
Johnny Zhang, The Assistant President at FEELM (Photo: Business Wire)
As a leading vaping technology provider and flagship brand of atomization tech company SMOORE, FEELM unveiled the advanced FEELM Max solution which boasts three major breakthroughs: the advanced heating technology of the Ceramic Coil S1, a constant power control system and mindful design.
With the first products featuring the FEELM Max solution about to launch in the UK and EU markets, the launch was attended by many top level representatives from many client companies including BAT, RELX International, Totally Wicked, and KIWI.
Setting New 800-Puff Benchmark for 2 ML E-Liquid
The coil technology journey began with first-generation cotton wick coils, progressed to second-generation cotton mesh coil, and has now developed into the era of third-generation ceramic coil technology with the FEELM Max being the latest manifestation of this industry innovation.
Designed to deliver a superior vaping experience, the innovative FEELM Ceramic Coil S1 brings cutting-edge coil technology that offers an increased puff count, setting a new benchmark in the market.
Benefitting from its cotton-free design and the resulting improvement of e-liquid utilization, the FEELM Max is able to boost puff count by more than 30% compared to cotton coil disposable solutions, providing 800 more puffs and setting a new benchmark for 2ml. This innovation allows products using the FEELM Ceramic Coil S1 to offer increased puff counts while remaining totally compliant with all local regulations.
In addition, the new S1 coil decreases the amount of impurities from the heating process by 78%, resulting in fresher breath and no unpleasant aftertaste. This is a significant stride towards ensuring a clean and silky vaping experience for consumers.
Electronic and Design Breakthroughs
The FEELM Max solution uses a constant power energy management system for stable vaping and over 95% vapor consistency. This technology improves taste consistency by 35%, which further enhances the user experience.
FEELM Max products showcase a transparent e-liquid tank for both aesthetics and user convenience. No longer will vapers have to guess how much e-liquid is left in their device because one quick look will let them know. The CMF Lab refines this design through specialized research and has developed a scientific ergonomic model for the vaping industry.
First Industrial End-To-End Whole-Chain Recycling Scheme
FEELM has also launched the first industrial whole-chain recycling scheme, collaborating with RELX International in the UK. Conscious of the potential harm of vapes ending up in landfills, FEELM has taken the responsibility for implementing a scheme that will facilitate vape recycling to a fuller extent, thereby minimising the environmental impact.
The company's commitment to making recycling more accessible demonstrates its dedication to environmental sustainability. As the initiative gains traction, it could serve as a model for other industries looking to implement eco-friendly practices and engage adult customers in sustainability efforts.
Shaping a Sustainable and Compliant Future with Partners
FEELM's success is not solely due to its innovative technology and the relentless pursuit of excellence, but also the strong collaboration it has forged with its clients and industry partners.
Bing Du, the CEO and founder of RELX International stated at the event: “Thanks to the groundbreaking technology of FEELM Max, and driven by our legendary partnership with FEELM, RELX International is on course to revolutionize the vaping experience across the globe.”
Liam Cagliarini, UK CEO of KIWI Vapor, the leading Italian brand, stated: "We aim to collaborate with FEELM on latest technology, and provide a consistency vaping experience for consumers."
Marcus Saxton, CEO of Totally Wicked, top British brand, added: "FEELM’s innovative technology has enhanced the consumer experience. As a partner of FEELM, Totally Wicked shares the responsibility of promoting sustainability in the atomization industry through active participation in the recycling system."
FEELM intends to continue pushing the boundaries of what's possible in vaping technology, while keeping its commitment to sustainability and compliance at the heart of its operations. The company's mission to shape a better vaping industry, not only for today but for generations to come, remains stronger than ever.
About FEELM
As a flagship tech brand belonging to SMOORE, FEELM is the world’s leading closed vape system solution provider. Based on the world's leading Ceramic Coil Heating Technology, FEELM combines authentic Flavor Reproduction Technology with innovative electronics technology, bringing ultimate sensation and premium vaping experience.
About SMOORE
Founded in 2009, SMOORE is a global leader in atomization technology solutions, covering reduced-risk products, medical, pharmaceutical, and beauty atomization technologies. With inter-disciplinary atomization research and a diverse product portfolio, SMOORE is committed to becoming an advanced platform, aspired to make life better.
With continuous R&D investment and leading manufacturing capacity, SMOORE has 14 technology research centers worldwide and products are available in more than 50 countries and regions. SMOORE announced IPO in Hong Kong on July 10, 2020.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230514005039/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom